TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06575426: A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

Sponsor: Otsuka Pharmaceutical Factory, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$4,317,660

Rescue Site Savings

+$2,850,220

Unlock Full NCT06575426 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06575426 Rescue Dossier →